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Ancient Missense Mutations in a New Member
of the RoRet Gene Family Are Likely to Cause
Familial Mediterranean Fever
The International FMF Consortium* Introduction
The hereditary periodic fever syndromes are a relatively
recently recognized group of inherited inflammatory dis-Summary
orders that are characterized by episodic, self-limited
bouts of fever accompanied by unexplained arthritis,Familial Mediterranean fever (FMF) is a recessively
inherited disorder characterized by dramatic episodes sterile peritonitis, pleurisy, and/or skin rash (reviewed
in Kastner, 1996). To date, three clinical diseases haveof fever and serosal inflammation. This report de-
scribes the cloning of the gene likely to cause FMF been identified in this class: the recessively inherited
familial Mediterranean fever (FMF, MIM249100) andfrom a 115-kb candidate interval on chromosome 16p.
Three different missense mutations were identified in Dutch type periodic fever (MIM260920, also known as
the hyperimmunoglobulinemia D syndrome), and theaffected individuals, but not in normals. Haplotype and
mutational analyses disclosed ancestral relationships dominantly inherited familial Hibernian fever (MIM142680).
In addition, there are a number of other related butamong carrier chromosomes in populations that have
been separated for centuries. The novel gene encodes clinically distinguishable conditions (Gertz et al., 1987;
Karenko et al., 1992) that have been described in casea3.7-kb transcript that is almostexclusively expressed
in granulocytes. The predicted protein, pyrin, is a reports but have not yet been organized into specific
nosologic entities.member of a family of nuclear factors homologous to
the Ro52 autoantigen. The cloning of the FMF gene Of the three well-defined hereditary periodic fever
syndromes, FMF is by far the most common and haspromises to shed light on the regulation of acute in-
flammatory responses. attracted the most investigative interest. FMF is seen
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primarily in individuals of non-Ashkenazi Jewish, Arme- et al., 1995) were found to be unstable. We therefore
established a highly redundant contig comprised ofnian, Arab, and Turkish background. In these popula-
tions, the carrier frequency has been estimated to be small-insert YACs, P1s, PACs, BACs, and cosmids that
completely spans the interval (Sood et al., 1997). Usingas high as 1:5 (Rogers et al., 1989; Daniels et al., 1995;
Yuval et al., 1995), raising speculation that heterozy- an independent panel of non-Ashkenazi Jewish families
and newly developed microsatellites from GeÂ neÂ thon, thegotes may have some selective advantage, perhaps
manifested by increased resistance to an as yet uniden- French FMF Consortium (1996) identified markers z600
kb apart defining the MEFV interval by intrafamilial re-tified infectious agent. Depending on poorly defined he-
reditary and environmental factors (Pras et al., 1982), combinants. By comparing FMF carrier chromosomes
in their panel with the ancestral haplotype noted above,homozygotes often develop progressive systemic amy-
loidosis from the deposition of the acute phase reactant the French Consortium found ªhistorical recombinantsº
that further narrowed the candidate interval to a z250serum amyloid A (SAA). Prior to prophylactic treatment
with colchicine, FMF amyloidosis was a significant kb YAC. Our own data defined a 285 kb candidate inter-
val by observed intrafamilial recombinants and an z200cause of renal failure and death in the Middle East. In
the absence of an accurate diagnostic test, FMF patients kb minimal region by historical recombinants (Balow et
al., 1997). Both of these sets of data are consistent inin countries where the disease is less prevalent often
experience years of attacks and several exploratory sur- their placement of the FMF gene.
We now report the cloning of the FMF gene fromgeries before the correct diagnosis is made and ade-
quate treatment with colchicine is begun. this 200 kb interval. Our strategy involved developing a
detailed transcript map from this region by a combina-FMF attacks are characterized by a massive influx of
polymorphonuclear leukocytes (PMNs) into the affected tion of exon amplification, direct cDNA selection, single-
pass sequencing of a minimal tiling path of cosmids,anatomic compartment. Inciting factors are unclear,
and, even off treatment, patients can sometimes inexpli- and, for selected areas, finished sequencing. During the
construction of the transcript map, we identified newcably go for long periods without symptoms, only to
relapse into a frequent pattern of attacks at some later microsatellites that permitted further refinement of the
candidate interval to the centromeric-most 115 kb. Us-time. At the biochemical level, patients have variously
been reported to have abnormal levels of a C5a inhibitor ing two trapped exons as probes, we isolated a 3.7 kb
clone from a leukocyte cDNA library. The protein prod-(Matzner and Brzezinski, 1984), neutrophil-stimulatory
dihydroxy fatty acids (Aisen et al., 1985), and dopamine uct is predicted to be 781 amino acids in length and is
a member of a family of proteins that includes the Ro52b-hydroxylase (Barakat et al., 1988), but none of these
findings has led to the identification of the genetic basis autoantigen (Itoh et al., 1991) and RFP (ret finger protein,
the gene encoded by the 59 half of the hybrid ret trans-of FMF.
In the absence of other functional clues, we undertook forming gene; Takahashi et al., 1988). We have identified
three missense mutations in the cloned cDNA, all ofa positional cloning approach to identify the FMF gene
(designated MEFV). Initial linkage studies placed MEFV which encode changes in the same highly conserved
C-terminal domain. None of the three mutations is pres-on chromosome 16p (Pras et al., 1992) in a panel of non-
Ashkenazi Jewish families. Linkage to this region has ent in any of a large panel of normal control chromo-
somes. Two of these mutations are found on FMF carriersubsequently been confirmed and extended to all four
major affected ethnic groups (Shohat et al., 1992; Pras chromosomes in populations that, in some cases, have
been geographically separated for over 2000 years, indi-et al., 1994; French FMF Consortium, 1996), although
differences in severity among subpopulations has sug- cating that most cases of FMF are descended from a
very ancient pool of founders, and suggesting commongested the possibility of allelic heterogeneity (Pras et al.,
1997). Early studies demonstrated a substantial founder origins for several Middle Eastern populations.
effect in the Moroccan Jewish population (Aksentijevich
et al., 1993), and as markers closer to MEFV have been
Resultsidentified, it has become apparent that a high percent-
age of all North African Jewish FMF carrier chromo-
Positional Cloning Strategysomes (93% in our hands) are descended from a com-
Figure 1 depicts schematically the recent steps in ourmon ancestor (French FMF Consortium, 1996; Levy et
positional cloning strategy. Based onearly genetic local-al., 1996; Balow et al., 1997). This same ancestral haplo-
ization data, we established a contig spanning the 1 Mbtype was observed in one third of the Armenian carrier
interval between D16S94 and D16S2622 (Sood et al.,chromosomes we have studied and in about 15% of
1997). Microsatellite markers from this interval definedIraqi Jewish FMF chromosomes.
a critical region of 285 kb (D16S468±D16S3376) basedUsing publicly available polymorphic markers, we nar-
on observed recombinations in a panel of 61 families,rowed the candidate region to an approximately 1 Mb
and a smaller candidate interval of z200 kb (D16S3082±interval lying between the polycystic kidney disease
D16S3373) based on historical recombinants. Tran-(PKD1) and tuberous sclerosis (TSC2) genes on the telo-
scripts were then identified by a combined strategy ofmeric end, and the CREB-binding protein (CREBBP)
exon amplification, direct cDNA selection, and single-gene on the centromeric end (Sood et al., 1996; see
pass sequencing. This led to the isolation of 9 full-lengthFigure 1). The extensive physical maps constructed
cDNA clones (8 of which were previously uncharacter-around these genes (Dackowski et al., 1996; Giles et al.,
ized), including 3 classical zinc finger genes, 2 members1997) did not, however, extend into the MEFV region,
and large insert YACs mapping to this interval (Doggett of the olfactory receptor family, and a novel caspase.
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Figure 1. Schematic Representation of the MEFV Region on Chromosome 16p13.3
(A) z1 Mb region over which a cosmid contig was constructed (Sood et al., 1997). PKD1, polycystic kidney disease 1; TSC2, tuberous sclerosis
2; RSTS, Rubinstein-Taybi syndrome; CREBBP, CREB binding protein gene.
(B) z285 kb candidate interval defined by intrafamilial recombination events in our panel of families (Balow et al., 1997). D16S3405±D16S3373
is the minimal candidate interval defined by historical recombinants in the present study.
(C) Representation of the genomic structure of the v75-1 gene. Shaded boxes represent exons; introns are drawn to scale. Numbers above
the boxes represent the size of the exons, in bp. Numbers below the boxes reflect the order of the exons, with (1) being the most 59.
The furthest centromeric of these 9 cDNAs, clone v75-1, interferon-inducible transcriptional regulator Staf-50
(Tissot and Mechti, 1995), and rpt-1, a mouse down-was isolated by solution hybridization of a leukocyte
cDNA library with biotinylated oligonucleotide probes regulator of IL-2 (Patarca et al., 1988). Homology to the
latter protein is in a domain extending from residuesderived from two exons trapped from PAC 273L24.
In parallel, analyzing finished sequence from z90 kb 385 to 550, while homology to the former two proteins
is particularly high through a domain at the C-terminalin the center of the D16S3082±D16S3373 interval, we
found twonew microsatellites, D16S3404 and D16S3405 end of v75-1 (double-boxed in Figure 2). This domain is
also found in the ret finger protein (RFP) and has been(Figure 1B). In one non-Ashkenazi Jewish family, evi-
dence for a historical recombination event that occurred termed an rfp (Takahashi et al., 1988) or B30.2 domain
(Vernet et al., 1993; Henry et al., 1997). Analysis with thebetween D16S3404 and D16S3405 in the highly con-
served non-Ashkenazi Jewish haplotype (designated SEG algorithm (Wootton, 1994) indicated a high likeli-
hood that this domain assumes a globular conformation.haplotype A) was observed, thereby excluding the re-
gion telomeric of D16S3405 (and four candidate genes Additional analyses of the putative protein product,
termed pyrin to connote its relationship to fever, indicateencoded therein) from further consideration.
that it is very positively charged, with a predicted pI .
8 and with lysine and arginine making up 13% of theCharacterization of cDNA v75-1
The translated v75-1 cDNA sequence is shown in Figure amino acid composition. Moreover, the PSORT algo-
rithm (Nakai and Kanehisa, 1992) detected two overlap-2, and the exon-intron structure deduced from the geno-
mic sequence of two cosmids is depicted in Figure 1C. ping nuclear targeting signals. The first is a four-residue
pattern composed of a histidine and three lysines (start-Although there is an excellent Kozak consensus (Kozak,
1996) at the initial methionine, the reading frame remains ing at residue 419), and the second is a Robbins/Ding-
wall consensus (boxed in Figure 2, residues 420±437;open in the cDNA upstream of this. Nevertheless, there
are no splice-acceptor consensus sequences or in- Robbins et al., 1991). In addition, a PROSITE search
(Bairoch et al., 1997) identified a bZIP transcription fac-frame methionines with good Kozak sequences before
the first stop upstream in genomic DNA, and the tran- tor basic domain (Shuman et al., 1990) at residues 266±
280. The region between residues 375 and 407 (denotedscript size by Northern blot (see below) is 3.7 kb, thus
suggesting that the sequence presented is full-length. by plus signs in Figure 2) contains an arrangement of
cystine and histidine residues with spacing that con-Consistent with the initial analysis of single-pass ge-
nomic sequence from this region, BLASTX (Altschul et forms closely to a B box±type zinc finger domain (Reddy
et al., 1992).al., 1990) demonstrated homologies with a number of
molecules implicated in inflammation. These include the Northern analysis using a probe with unique sequence
from exon 2 of v75-1 showed an abundant z3.7 kb52 kDa Ro/SS-A ribonucleoprotein, against which pa-
tients with systemic lupus erythematosus (SLE) and SjoÈ - transcript in peripheral blood, but there was no signifi-
cant expression in 14 other normal tissues, includinggren's syndrome frequently make autoantibodies, the
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Figure 2. The Predicted Protein Sequence Encoded by cDNA v75-1
The boxed segment from aa 266 to 280 is a bZIP transcription factor basic domain; the boxed segment from aa 420 to 437 is a Robbins/
Dingwall consensus nuclear targeting signal. The segment indicated by plus signs between residues 375 and 407 is a potential B-box zinc
finger domain. The region double-boxed from residue 577 to 757 is a rfp, or B30.2, domain. Within this box, the three mutated amino acids
are double-underlined.
spleen and thymus (Figure 3A). Bone marrow and lymph 2080 causing a substitution of valine for methionine
(M694V), was observed in a large number of affectednodes were also negative for v75-1 expression (data not
shown). Among a panel of tumor cells, only the SW480 individuals bearing four apparently distinct disease-
associated haplotypes (see below). The third, a T→Ccolorectal adenocarcinoma cell line showed significant
expression. Expression of v75-1 was absent in HL-60 transition at nt 2177, results in the substitution of alanine
for valine (V726A) and was observed in affected individu-promyelocytic leukemia, K-562 erythroleukemia, and
Burkitt's lymphoma. Even by RT±PCR, message was als bearing the C haplotype in a Druze family and in
other FMF patients and carriers bearing this haplotype.not detectable in a peritoneal fibroblast cell line, or in
fetal or adult brain (data not shown). Figure 3B demon- When the remaining nine exons of v75-1 were se-
quenced in these haplotypes, no additional mutationsstrates pyrin expression in PMNs, but not in lympho-
cytes. We also found that pyrin is not expressed in were identified.
monocytes purified from peripheral blood (data not
shown). Ancestral Relationships Among FMF
Carrier Haplotypes
Table 1 explores the relationship of v75-1 mutations withMutational Analyses
Direct sequencing of RT±PCR products or amplified ex- specific disease-associated haplotypes in our study
population. Haplotype A is the disease-associated hap-ons from the eight cDNAs telomeric to v75-1 failed to
identify disease-associated mutations. In contrast, three lotype observed in a very high percentage of North Afri-
can Jewish carrier chromosomes, but that is seen lessdifferent missense mutations were identified in exon 10
of v75-1 (Figure 4) after screening a total of 165 individu- frequently in the Armenian and Iraqi Jewish populations.
Haplotypes F and G are additional North African Jewishals from 65 families. The first mutation, a G→C transver-
sion at nt 2040 that results in the substitution of isoleu- disease-associated haplotypes, each observed in a sin-
gle family, that appear by microsatellite analysis to becine for methionine (M680I), was observed in the
homozygous state in the affected offspring of a single different from the A haplotype (Table 1A). Haplotype B
is yet another distinct FMF haplotype observed in theArmenian family. The second, an A→G transition at nt
Ancient Pyrin Mutations in FMF
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Figure 3. Expression Profile of the v75-1
Gene
(A) Results of hybridization of a probe derived
from exon 2 on multiple-tissue Northernblots.
A transcript of 3.7 kb is present in peripheral
blood leukocytes and colorectal adenocarci-
noma SW480. HL-60, promyelocytic leuke-
mia; K-562, erythroleukemia; MOLT4, lym-
phoblastic leukemia; A549, lung carcinoma;
G361, melanoma.
(B) Hybridization of the same exon 2 probe on
Northern blot with mRNA from purified PMNs
and lymphocytes. PMN lanes represent prep-
arations from different individuals. A b-actin
control is shown below.
Iraqi Jewish population, while the C haplotype is seen For any given haplotype, only one mutation was pres-
in patients from several different ethnic groups. The J ent. Altogether, these three mutations accounted for 78
and K haplotypes have only been observed in Armenian carrier chromosomes in our panel. There were several
affected individuals. Table 1A indicates no easily dis- other carrier chromosomes with different microsatellite
cernible relationship among these haplotypes at the haplotypes for which we did not observe any of these
level of microsatellites, except that haplotypes J and K three mutations (these latter carrier chromosomes have
are identical in the region from D16S3403 to D16S2617. thus far only been screened for exon 10 mutations). In
Table 1B summarizes data on 11 single nucleotide four separate families we have observed M694V/V726A
polymorphisms (SNPs) that we have identified from compound heterozygotes. In one such family, the par-
within the v75-1 gene for each of the haplotypes defined ents are of Ashkenazi and Iraqi Jewish ancestry, with
in Table 1A. Nine of these polymorphisms represent the Ashkenazi father carrying the V726A mutation on
synonymous substitutions within exons of this gene, the C haplotype FMF chromosome. This haplotype es-
while the remaining two are seen in introns 4 and 6. The tablishes an ancestral link between Ashkenazi Jews,
A, F, and G haplotypes are identical at all 11 polymor- who have lived in Eastern Europe for the last 1500 years,
phisms, and, although the B haplotype differs from A, F, and the Druze, who have lived in isolated communities
and G at the 59 end of the gene, SNPs for all 4 haplotypes in what is now Israel and Lebanon for the last z1000
converge beginning at exon 3. Similarly, SNPs for the years. The only other Ashkenazi Jewish carrier whom
C, J, and K haplotypes also converge by exon 3. The we have genotyped also has the V726A mutation.
ªAFGBº and ªCJKº core SNP haplotypes from exon 3
The M680I, M694V, and V726A mutations were not
to 10 were also observed on significant numbers of
present on any of 105 normal chromosomes in our study
ethnically matched normal chromosomes (not shown).
population (defined by haplotype analysis in well-char-Table 1C, which correlates haplotypes with v75-1 mu-
acterized families), nor in almost 200 North Americantations, suggests that ancestral relationships among
control chromosomes. It is also noteworthy that al-these subsets of chromosomes are likely. Thus, the con-
though no A haplotype±bearing noncarrier chromo-vergent A, F, G, and B haplotypes all bear the M694V
somes could be identified, two noncarrier chromosomesmutation, while we have not observed M694V on haplo-
with the B haplotype (both by microsatellites and SNPs)types that do not share the AFGB core SNPs. Similarly,
did not have the M694V mutation, further strengtheningArmenian haplotypes J and K converge within v75-1 and
the connection between the presence of the mutationboth bear the same M680I mutation, while this mutation
and disease. Moreover, 42% of a panel of 24 Middlehas not been observed on haplotypes that do not have
Eastern normal chromosomes bear the AFGB SNP corethe CJK core SNPs. The C haplotype bears the same
haplotype but do not carry M694V, which is further evi-convergent SNP haplotype as J and K, suggesting an
dence that M694V is disease-causing, and not a privateindependent mutational event on an ancestral CJK-type
chromosome. polymorphism.
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observation of normal chromosomes that bear disease-
associated microsatellite and SNP haplotypes but do
not have the M680I,M694V, or V726Amutations is strong
evidence that these are not just haplotype-specific poly-
morphisms.
While these genetic arguments firmly establish the
identity of v75-1 as the FMF gene, data on v75-1 tissue
distribution are highly consistent with theclinical pheno-
type. Based on the nature of the inflammatory infiltrate
and the anatomic localization of inflammation in FMF,
MEFV gene expression might be predicted to be ob-
served in granulocytes and/or serosal cells. Multiple-
tissue Northern blots demonstrated high levels of ex-
pression in peripheral blood leukocytes, but not in lymph
node, spleen, or thymus, which are comprised largely
of lymphocytes. From this we deduced that pyrin is most
likely expressed primarily in mature granulocytes, an
inference that was subsequently confirmed by direct
observation.
Computational analyses of wild-type and mutant pyrin
molecules suggest a mechanism by which the mutations
identified may cause disease. All three mutations are
clustered within 46 amino acids of one another in the
highly conserved B30.2 (rfp) globular domain at theFigure 4. DNA Sequence Electropherograms Demonstrating the
C-terminal end of the predicted protein, and they proba-M680I, M694V, and V726A Substitutions
bly affect the secondary structure of this domain. BasedFor each mutation, individuals who are homozygous for the normal
on BLASTX homologies and its restriction to granulo-allele are shown at the top, heterozygotes between the normal and
mutant allele are shown in the middle, and homozygotes for the cytes, pyrin is likely to be a nuclear factor that controls
mutation are shown at the bottom. On the pedigree diagram, the the inflammatory response in differentiated PMNs.
heterozygote is shown as an open red symbol, and the homozygote Given that FMF is a disease of excessive inflammation,
for the mutation is shown as a closed red symbol. The control for and that pyrin is homologous to rpt-1, a known down-
the M680I mutation is individual 76-06, the control for M694V is 76-
regulator of inflammation, pyrin may be a negative auto-02, and the control for V726A is 3-01.
regulatory molecule in PMNs. The FMF-associated mu-
tations and resultant pyrin structural changes would
then, after some undefined event that triggers inflamma-Discussion
tion, prevent the normal pyrin-mediated negative feed-
back loop.
In this paper, we describe the molecular cloning of a
None of these three mutations results in a truncated
new cDNA, v75-1, from the familial Mediterranean fever
protein, and the periodic nature of inflammatory attacks
candidate region on chromosome 16p13.3 and present in FMF is consistent with a protein that functions ade-
compelling evidence that this gene is MEFV, the gene quately at steady state but decompensates under
causing FMF. The cornerstone of the argument equating stress. Several other diseases with periodic manifesta-
v75-1 with MEFV is the identification of three different tions follow this paradigm, including sickle cell anemia
v75-1 mutations on FMF carrier chromosomes in multi- (b-globin; Weatherall et al., 1995) and hyperkalemic peri-
ple ethnic groups, mutations that are not seen in a panel odic paralysis (adult skeletal muscle sodium channel;
of almost 300 normal control chromosomes. PtaÂ cek et al., 1991). Both are characterized by missense
It is extremely unlikely that the substitutions we have mutations encoding an abnormal protein with reduced
identified in v75-1 are actually polymorphisms in tight function. Patients experience symptoms when environ-
linkage disequilibrium with ªrealº mutations on a nearby mental factors (hypoxia or acidosis in the case of sickle
gene. This hypothesis would require that there be three cell, excess consumption of potassium in periodic paral-
such v75-1 polymorphisms on three different haplo- ysis) induce additional conformational changes in the
types, each in perfect linkage disequilibrium with the protein (sickle cell) or destabilize a delicate equilibrium
mutations on the real FMF gene. While not impossible, (periodic paralysis). Similarly, environmental triggers
such a scenario is at the least unnecessarily complex. may play a role in FMF, and the identification of pyrin
It is also unclear where such a closely linked gene would should provide clues regarding the proximal steps in
be located. The historical recombinants at the 59 (centro- the cascade that leads to an attack.
meric) end of v75-1 exclude the interval between Just as protein-truncating mutations in globin pro-
D16S3373 and v75-1. On the telomeric side, the 59 end duce thalassemia and not sickle cell disease, more pro-
of a novel zinc finger gene is located within 10 kb of the found loss-of-function mutations in pyrin may produce
39 end of v75-1, but thorough screening has revealed no a phenotype much different from FMF. It is even conceiv-
mutations in this latter gene (data not shown). Moreover, able that the total lack of pyrin may lead to generalized,
there are no trapped exons, direct-selected cDNAs, or uncontrolled inflammation and may therefore be embry-
expressed sequence tag (EST) hits that map to the inter- onically lethal. Mouse models may shed light on these
questions.val between them. Finally, and most importantly, the
Ancient Pyrin Mutations in FMF
803
Table 1. FMF Carrier Haplotypes and cDNA v75-1 Mutations
A. Extended Microsatellite Haplotypes
Microsatellite Markersa
Haplotype Ethnic Grpb S468 S3082 S3403 S3405 S3404 S3370 S2617 ↓ S3373 S3275 S3376
A NAfJ, IrJ, Arm 212 148 1100 165 118, 122 153 104 185 184 211
F NAfJ 204 152 1000 165 118 149 104 187 188 215
G NAfJ 202 150 1000 185 94 141 107 187 184 211
B IrJ 206 138 1000 187 94 141 110 185 186 217
C IrJ, AshJ, Dr, Arm 202 140 1100 165 110 149 107nc 187 186 201
J Arm 202 136 1100 165 118 149 107n 183 188 215
K Arm 202 132 1100 165 118 149 107n 185 196 211
B. cDNA v75-1 Intragenic Haplotypes
Single Nucleotide Polymorphismsd
32.1 32.2 32.3 32.4 33.1 35.1 35.2 35.3 39.1
Haplotype Ethnic Grp 306 414 495 605 901 i4.1e 1422 1428 1530 i6.1f 1764
A NAJ, IrJ, Arm C G A A C A G A T C A
F NAfJ C G A A C A G A T C A
G NAfJ C G A A C A G A T C A
B IrJ T A C G C A G A T C A
C IrJ, AshJ, Dr, Arm T A C G T G A G C T G
J Arm T A C G T G A G C T G
K Arm C G A G T G A G C T G
C. cDNA v75-1 Mutations
Mutation aa Haplotypes Normal Chromosomes
2040 G→C Met680IIe J (1/1) 0/293
K (1/1)
2080 A→G Met694Val A (62/62) 0/295
B (5/5)
F (1/1)
G (1/1)
2177 T→C Val726Ala C (8/8) 0/283
aIn each case the ªD16º has been omitted at the beginning of the locus designation. The position of MEFV relative to these markers is indicated
by the arrow. Microsatellites are listed telomeric to centromeric, from left to right.
bNAfJ 5 North African Jewish, AshJ 5 Ashkenazi Jewish, IrJ 5 Iraqi Jewish, Arm 5 Armenian, Dr 5 Druze.
cDenotes the presence of a null allele with standard D16S2617 primers, but 107 bp amplicon when an alternative primer pair is used (Balow
et al., in press).
dDesignated by exon or intron; 32.1 indicates the first polymorphism in exon 2. Below each designation is the nucleotide position in the
sequence, with 1 being the adenosine in the ATG initiation codon. Note that the polymorphisms are listed 59 to 39, from left to right, which is
the opposite orientation on the chromosome from that shown in (A).
eIntron 4, nucleotide position 1356 1 43.
FIntron 6, nucleotide position 1610 1 95.
It would appear that at least some of the phenotypic role of pyrin in the homeostatic control of inflammation
is consistent with heterozygotes exhibiting heightenedvariation in FMF may be attributable to the difference
between the M694V and V726A mutations. The M694V responses to a specific pathogen or class of pathogens.
The strikingly high gene frequencies for FMF in moremutation is very common in the populations with the
highest incidence of systemic amyloidosis (especially than one Middle Eastern population could then be ex-
plained by increased heterozygote resistance to suchNorth African Jews), while V726A is seen in populations
in which amyloid is less common (Iraqi and Ashkenazi an organism. Since the gene frequency for FMF is much
lower in the East European Ashkenazi Jewish populationJews, Druze, and Armenians). Nevertheless, M694V-
associated haplotypes can comprise a significant mi- (Yuval et al., 1995), it is possible that such a selective
factor would have been endemic to the Mediterraneannority of carrier chromosomes in populations where se-
vere amyloidosis is exceedingly rare. One possible basin. The identification of pyrin should lead to testable
hypotheses regarding the host inflammatory responseexplanation could be that the ªmilderº V726A mutation
is ªprotectiveº against amyloid, in which case M694V/ in FMF heterozygotes.
Our data indicate that the M694V and V726A muta-M694V homozygotes would be amyloid-prone but
V726A homozygotes and compound heterozygotes tions are very old. Based on the convergence of several
carrier haplotypes, it is likely that all modern M694Vwould not.
Although founder effects clearly have played a role in chromosomes are descended from a common founder.
This mutation is seen on the B FMF haplotype commonlythe population genetics of FMF, selection for heterozy-
gotes remains an attractive hypothesis. The probable observed in Iraqi Jews, a group that remained relatively
Cell
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Figure 5. Multiple Sequence Alignment of
the C-Terminal End of Human Pyrin
Sequences shown have statistical similarity
as assessed by BLAST (Altschul et al., 1990).
Search cutoffs used to identify homologs
were a Karlin-Altschul score of two aligned
sequences > 70 with a probability < 1023. At
each position, residues occurring in a major-
ity of the sequences are shown in inverse
type. The numbering scheme at the top of the
figure is based on the sequence of pyrin. The
positions of secondary structural elements in
the wild-type pyrin (here, all b sheets) as pre-
dicted by the profile neural network method
PHDsec (Rost and Sander, 1993, 1994) are
shown as bold, horizontal arrows below the
alignment. The residues altered in the three
mutants are indicated by downward-pointed
arrowheads above the alignment. hum-RFP,
RET finger protein (SWISS-PROT P14373);
xla-xnf7, nuclear phosphoprotein xnf7, Xeno-
pus laevis (PIR A43906); pwa-A33, zinc-bind-
ing protein A33, Pleurodeles waltl (SWISS-
PROT Q02084); hum-SS-A/Ro, 52 kDa RO
protein (SWISS-PROT P19474); hum-afp, acid
finger protein (GenBank U09825); hum-BT,
butyrophilin (GenBank U90552); hum-efp, es-
trogen-responsive finger protein (PIR A49656);
hum-B30-2, B30-2 gene, (PRF 2002339); pig-
RFB30, ring finger protein RFB30, Sus scrofa
(EMBL Z97403); hum-Staf-50, transcription
regulator Staf-50 (PIR A57041).
isolated from the rest of the Jewish population from the between these two structural elements is also highly
conserved, suggesting that precise orientation of thetime of the Babylonian captivity (z2500 years ago) until
the formation of the state of Israel. Similarly, the obser- two domains with respect to one another is required for
function. The conservation of the rfp domain (Figure 5)vation of the V726A mutation and C microsatellite haplo-
type in Armenians, Ashkenazi Jews, and Druze FMF in molecules as diverse as butyrophilin (a milk protein
with probable receptor function; Jack and Mather, 1990),patients establishes a historical lower boundary on the
age of this mutation of perhaps 2000 years. Ro52 (a ribonucleoprotein that is autoantigenic in pa-
tients with SLE and SjoÈ gren's syndrome), A33 (a factorIt is also possible, of course, that the M694V mutation,
and its surrounding SNPs, has been transferred to four that binds polytene chromosomes in the newt; Bellini
et al., 1993),and xnf7 (a factor that binds mitotic chromo-different haplotypes by interchromosomal gene conver-
sion rather than by meiotic recombination events. In that somes in the frog; Reddy et al., 1991) is remarkable; the
sequence identity among these proteins ranges fromcase, the estimation of the age of the original founder
mutation would not be possible. Finally, the possibility 40% to 60%. Scrutiny of B30.2 mutations in pyrin may
provide insights into this evolutionarily conserved butof multiple independent origins of M694V and M680I
cannot be formally excluded, but the concordance of poorly understood domain.
The identification of pyrin mutations as the cause ofthe SNP haplotypes close to the mutation (Table 1B and
1C) renders this possibility rather unlikely. FMF will substantially advance our understanding of this
disorder and will provide a tool to address questionsThe identification of pyrin as the molecule responsible
for FMF also focuses interest on the RoRet family of ranging from population genetics to structural biology.
It represents the first step in the delineation of an impor-proteins, all of which share a B-box zinc finger as well
as a 170 amino acid rfp (B30.2) domain. The spacing tant new pathway in the control of inflammation.
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Experimental Procedures identified by visual inspection and hybridization to DNA fragments
from the FMF critical region, with several exons identified more than
one time.Patients and DNA Samples
Forty-four families of non-Ashkenazi Jewish descent (18 Moroccan,
14 Libyan, 5 Tunisian, 2 Egyptian, and 5 Iraqi) and 5 Arab/Druze cDNA Identification by Solution Hybridization
families were identified and sampled at the Chaim Sheba Medical Solution hybridizations were carried out using the GeneTrapper
Center in Tel-Hashomer, Israel. Twelve Armenian families were re- cDNA Positive Selection System (Life Technologies, Gaithersburg,
cruited from Cedars-Sinai Medical Center in Los Angeles. Details MD). Two trapped exons, v66 and v75, were used as starting mate-
of this panel have been previously described (Balow et al., 1997). rial. PCR screening of Superscript cDNA libraries (Life Technologies,
One additional Ashkenazi/Iraqi Jewish family was also studied. The Gaithersburg, MD) derived from human brain, liver, leukocytes,
diagnosis of FMF in all families was according to established clinical spleen, and testis were used to determine the tissue-specific ex-
criteria (Sohar et al., 1967). Patient consent was obtained from parti- pression of these exons. The leukocyte cDNA library was used in
cipants in the study after approval by the human experimentation further experiments since it showed significant expression of v66
committees at each institution. DNA was extracted from whole blood and v75 exons. GeneTrapper experiments were performed with
or from Epstein-Barr virus±transformed lymphocytes by standard sense and antisense primers from both exons, assuming both orien-
techniques. tations of these exons in the putative transcript. The following oligo-
nucleotides were synthesized and PAGE-purified: v66GT1: AAGCTC
ACT GCC TTC TCC TC; v66GT2: GAG GAG AAG GCA GTG AGCGenotyping
TT; v75GT1: GAC TTG GAA ACA AGT GGG AG; v75GT2: CTC CCAPatients were genotyped as previously described (Balow et al.,
CTT GTT TCC AAG TC. Oligos were biotinylated and hybridized to1997). Additionally, genotyping by PCR was carried out with three
single-stranded DNA from the leukocye cDNA library (one primernew markers that were developed in this study and are described
per reaction), followed by cDNA capture using paramagnetic strep-here (D16S3403, D16S3404, and D16S3405). Sequences of oligonu-
tavidin beads and repair using the corresponding nonbiotinylatedcleotides and PCR conditions used to amplify these markers are
oligos. Colony hybridization of lifts using 32P-dCTP end-labeledavailable from the Genome Database.
oligos was used to identify positive clones. Gel-purified inserts from
these clones were hybridized to cosmid contig blots to distinguishDirect cDNA Selection
cDNA clones mapping to the FMF region from false positive clonesCosmids, BAC, and P1 clones in the FMF candidate region were
due to homologous domains. All positive clones were identified bybiotinylated using BioPrime (Life Technologies, Gaithersburg, MD).
the primers v66GT2 and v75GT2, and no clones were identified bycDNAs were prepared from combined mRNA from fetal brain, fetal
the other set of primers.liver, and human lymph node by reverse transcription and ligation
of an EcoRI/NotI adaptor, which also served as a PCR primer, to
Oligonucleotides for Exon Amplificationsecond-strand cDNAs. cDNAs were directly hybridized to biotinyl-
Oligonucleotides used to amplify pyrin exons were as follows (allated templates that were recovered using streptavidin-labeled mag-
oligo sequences aregiven 59 to 39): exon 1 forward, AACCTGCCTTTTnetic beads. Conditions for blocking, hybridization, binding, and
CTTGCTCA; exon 1 reverse, CACTCAGCACTGGATGAGGA; exon 3elution of cDNAs from magnetic beads (Dynal) were as described
forward, GAACTCGCACATCTCAGGC; exon 3 reverse, AAGGCCCA(Parimoo et al., 1991). After two rounds of selection, eluted cDNAs
GTGTGTCCAAGTGC; exon 4 forward, TTGGCACCAGCTAAAGATwere amplifiedwith CUA-tailedEcoRI/NotI adaptor primers and sub-
GGC; exon 4 reverse, TCTCCCTCTACAGGGATGAGC; exon 5 for-cloned into the pAMP10 vector (Life Technologies, Gaithersburg,
ward, TATCGCCTCCTGCTCTGGAATC; exon 5 reverse, CACTGTGGMD) to yield libraries of selected cDNAs. Recombinant clones were
GTCACCAAGACCAAG; exon 6 forward, TCCAGGAGCCCAGAAGTAarrayed on blots. Clones that hybridized to either repetitive or ribo-
GAG; exon 6 reverse, TTCTCCCTATCAAATCCAGAG; exon 7somal sequences were excluded from further analysis. To confirm
forward, AGAATGTAGTTCATTTCCAGC; exon 7 reverse, CATTTCTGtheir origin, unique clones were individually hybridized to EcoRI
AACGCAGGGTTT; exon 8/9 forward, ACCTAACTCCAGCTTCTCTCdigests of cosmid/BAC/P1 DNAs and DNAs from chromosome 16±
TGC; exon 8/9 reverse, AGTTCTTCTGGAACGTGGTAG; exon 10aspecific human-hamster hybrid lines. Clones were then hybridized
forward, CCAGAAGAACTACCCTGTCCC; exon 10a reverse, AGAGCto each other and were binned into groups. Representative clones
AGCTGGCGAATGTAT; exon 10b forward, GAGGTGGAGGTTGGAGof each group were hybridized to multiple-tissue Northern blots and
ACAA; exon 10b reverse, TCCTCCTCTGAAATCCATGG.sequenced.
Northern Blot AnalysisExon Trapping
To determine transcript size and level of expression in various tis-Exon trapping was performed on PAC clone 273L24 (Sood et al.,
sues, multiple-tissue Northern blots (Clontech) were hybridized with1997) as previously described (Buckler et al., 1991). PAC clone
probes derived from various exons of the gene. These exons were273L24 was partially digested with Sau 3AI. The reaction products
amplified and purified as part of the sequencing protocol for muta-were size-fractionated by agarose gel electrophoresis, and DNA
tion analysis. Larger exons (2, 5, and 10) were labeled by random-fragments 2 kb and larger were isolated from the gel. Partially di-
priming using Stratagene Prime-It Kit and 32P-dCTP (ICN). Hybridiza-gested DNA (50 ng) was ligated with 10 ng of exon-trapping vector
tion and washing of blots were essentially as described in SambrookpSPL3 that had been previously cleaved with BamHI and dephos-
et al. (1989), except using Hybridisol I (Oncor) prepared hybridizationphorylated with calf intestinal alkaline phosphatase (Promega, Madi-
buffer. Hybridization was detected by autoradiography, with 4 hourson, WI). Ligation products were electroporated into E. coli DH12B,
exposures. Northern blots with mRNA from highly purified peripheraland the electroporated cells cultured en mass in LB broth with 200
blood lymphocytes, PMNs, and monocytes were the kind gift of Drs.mg/ml ampicillin for 16 hours at 378C with shaking. DNA prepared
H. Lee Tiffany and Harry Malech.from the culture was used to transfect COS-7 cells (ATCC 30-2002)
using lipofectACE reagent (Life Technologies, Gaithersburg, MD).
Total RNA was isolated from transfected COS-7 cells with Trizol Mutation Detection by Fluorescent Sequencing
Approximately 100 ng of genomic DNA template was used in PCRreagent (Life Technologies) followed by ethanol precipitation. First-
strand cDNAs of transcription products from pSPL3 were primed reactions to amplify exons and flanking intronic sequences ac-
cording to the supplier's recommendations for AmpliTaq Gold (Per-with the oligonucleotide SA2. Specific amplification of trapped ex-
ons was as follows: PCR primed with oligonucleotides SA2 and SD6 kin Elmer, Branchburg, NJ) and Advantage-GC Genomic PCR Kit
(Clontech, Palo Alto, CA). The PCR primers were tailed with one ofwas performed, followed by digestion of the PCR products with
BstXI. A second PCR reaction using the digestion products was the following sequences: -21M13 forward: GTAAAACGACGGC
CAGT; -28 M13 reverse: CAGGAAACAGCTATGACCAT; -40 M13 for-primed with oligonucleotides dUSD2 and dUSA4. The resulting DNA
fragments were cloned into pAMP10 vector and sequenced. Two ward: GTTTTCCCAGTCACGACG. After amplification, reactions
were run on 1% agarose gels and gel-purified using either QIAquickhundred clones were sequenced and 20 independent exons were
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gel extraction kit (QIAGEN, Santa Clarita, CA) or Microcon/Micro- Gertz, M.A., Petitt, R.M., Perrault, J., and Kyle, R.A. (1987). Autoso-
mal dominant familial Mediterranean fever-like syndrome with amy-pure/Gel Nebulizer system(Amicon, Beverly, MA). Alternatively,PCR
loidosis. Mayo Clin. Proc. 62, 1095±1100.products were column-purified with Microcon-100 (Amicon). Puri-
fied amplicons were sequenced with dye primer chemistry (PE Ap- Giles, R.H., Petrij, F., Dauwerse, H.G., den Hollander, A.I., Lushni-
plied Biosystems, or Amersham, Cleveland, OH). Sequencing reac- kova, T., van Ommen, G.-J.B., Goodman, R.H., Deaven, L.L., Dog-
tions were ethanol-precipitated and run on an ABI 377 automated gett, N.A., Peters, D.J.M., and Breuning, M.H. (1997). Construction
sequencer. Sequence data were analyzedwith eitherAutoassembler of a 1.2 Mb contigsurrounding, and molecular analysis of, the human
1.4 (PE Applied Biosystems, Branchburg, NJ) or Sequencher 3.0 CREB-binding protein (CBP/CREBBP) gene on chromosome
(Gene Codes Inc., Ann Arbor, MI). 16p13.3. Genomics 42, 96±114.
Henry, J., Ribouchon, M.-T., Offer, C., and Pontarotti, P. (1997).
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